At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AGIO Agios Pharmaceuticals
Post-Market Trading 11-22 19:03:34 EST
55.68
+0.14
+0.25%
盘后55.68
+0.000.00%
16:48 EST
High56.82
Low54.73
Vol456.10K
Open55.78
D1 Closing55.54
Amplitude3.76%
Mkt Cap3.18B
Tradable Cap2.81B
Total Shares57.03M
T/O25.49M
T/O Rate0.90%
Tradable Shares50.52M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Leerink Partners Sticks to Their Hold Rating for Agios Pharma (AGIO)
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.